PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 21170561-1 2011 The Co(III) complex of 1,4,7,10-tetraazacyclododecane has been employed as the catalytic center of target-selective peptide-cleaving catalysts in previous studies. cyclen 23-53 mitochondrially encoded cytochrome c oxidase III Homo sapiens 4-11 9-149 10353071-7 1999 However, micronized fenofibrate could significantly decrease plasma fibrinogen levels, whereas atorvastatin evoked a small increase. Fenofibrate 20-31 fibrinogen beta chain Homo sapiens 68-78 11942772-9 2002 CONCLUSION: Fenofibrate and gemfibrozil induced similar variations from baseline values in triglycerides, HDL cholesterol, apolipoprotein B, and fibrinogen, but the decreases in total and LDL cholesterol levels were greater with fenofibrate, in this group of patients with primary hyperlipidemia. Fenofibrate 12-23 fibrinogen beta chain Homo sapiens 145-155 12017210-9 2002 The addition of micronised fenofibrate significantly decreased plasma fibrinogen levels as well as total cholesterol, low-density lipoprotein cholesterol, apolipoprotein B (ApoB) and triglycerides, and increased high-density lipoprotein cholesterol and ApoA, levels. Fenofibrate 27-38 fibrinogen beta chain Homo sapiens 70-80 10216095-6 1999 The suppression of fibrinogen expression was dose-dependent and was already evident after 1 day at the highest dose of fenofibrate tested (0.5% [wt/wt]). Fenofibrate 119-130 fibrinogen beta chain Homo sapiens 19-29 10216095-7 1999 Nuclear run-on experiments showed that the decrease in fibrinogen expression after fenofibrate occurred at the transcriptional level, as exemplified for the gene for the Aalpha-chain. Fenofibrate 83-94 fibrinogen beta chain Homo sapiens 55-65 10216095-13 1999 On treatment with 0.2% (wt/wt) fenofibrate, a significant decrease in plasma fibrinogen to 77% +/- 10% of control levels and in hepatic fibrinogen Aalpha-chain mRNA levels to 65% +/- 12% of control levels was seen in (+/+) mice, but not in (-/-) mice. Fenofibrate 31-42 fibrinogen beta chain Homo sapiens 77-87 10216095-13 1999 On treatment with 0.2% (wt/wt) fenofibrate, a significant decrease in plasma fibrinogen to 77% +/- 10% of control levels and in hepatic fibrinogen Aalpha-chain mRNA levels to 65% +/- 12% of control levels was seen in (+/+) mice, but not in (-/-) mice. Fenofibrate 31-42 fibrinogen beta chain Homo sapiens 136-146 11770837-9 2001 Compared with the control subjects (2.91 +/- 0.35 g/l), fibrinogen levels before treatment were higher in patients with dyslipidemia treated with ciprofibrate (3.42 +/- 0.59 g/l, NS) and fenofibrate (3.65 +/- 1.10 g/l, p < 0.05). Fenofibrate 187-198 fibrinogen beta chain Homo sapiens 56-66 10460070-0 1999 Fenofibrate decreases plasma fibrinogen, improves lipid profile, and reduces uricemia. Fenofibrate 0-11 fibrinogen beta chain Homo sapiens 29-39 10460070-2 1999 This 2-year trial was designed to assess the effect of fenofibrate on fibrinogen and, as secondary end points, on lipid profile and uric acid in patients with dyslipidemia. Fenofibrate 55-66 fibrinogen beta chain Homo sapiens 70-80 10460070-5 1999 The effect attributable to fenofibrate was a decrease of 15% in fibrinogen, 26% in the ratio low-density lipoprotein cholesterol to high-density lipoprotein cholesterol (-20% low-density lipoprotein cholesterol, +10% high-density lipoprotein cholesterol), 34% in triglycerides (median), and 13% in uric acid (P < .0001 for all). Fenofibrate 27-38 fibrinogen beta chain Homo sapiens 64-74 9655393-8 1998 In hyperlipidaemic patients, fenofibrate treatment decreases the plasma concentrations of interleukin-6, fibrinogen and C-reactive protein. Fenofibrate 29-40 fibrinogen beta chain Homo sapiens 105-115 8843189-11 1996 However, with fenofibrate therapy, in addition to comparable lipoprotein changes seen with fish oil, fibrinogen levels and plasma and blood viscosity decreased in patients with FDL. Fenofibrate 14-25 fibrinogen beta chain Homo sapiens 101-111 8117177-6 1994 Only fenofibrate decreased total triglyceride levels in type IIb, Lp(a) lipoprotein levels in patients with high baseline values, and fibrinogen. Fenofibrate 5-16 fibrinogen beta chain Homo sapiens 134-144 8847874-7 1996 Only fenofibrate, not simvastatin, decreased both fibrinogen (-10.3 vs. + 3.6%) and uric acid (-25% vs. no change) in type IIa and type IIb patients. Fenofibrate 5-16 fibrinogen beta chain Homo sapiens 50-60 7857385-8 1994 In conclusion, micronised fenofibrate at a daily dose of 200 mg had significant lipid-modifying properties but also exhibited a beneficial effect on other related risk factors such as fibrinogen reduction. Fenofibrate 26-37 fibrinogen beta chain Homo sapiens 184-194 8117177-11 1994 However, fenofibrate exhibits a significant effect on other established risk factors, such as total triglyceride, fibrinogen, and Lp(a) lipoprotein levels, and accordingly has a broader spectrum of activity than simvastatin. Fenofibrate 9-20 fibrinogen beta chain Homo sapiens 114-124 27424313-12 2016 Otherwise, combination and fenofibrate significantly reduced apolipoprotein B and non-HDL cholesterol and improved flow-mediated dilation and reduced CRP and fibrinogen to a similar extent. Fenofibrate 27-38 fibrinogen beta chain Homo sapiens 158-168 8236126-4 1993 After 1 month of therapy, plasma fibrinogen significantly decreased by 9% and 15% in fenofibrate and bezafibrate groups respectively and increased by 19% in gemfibrozil treated patients. Fenofibrate 85-96 fibrinogen beta chain Homo sapiens 33-43 8236126-7 1993 The fibrinogen lowering effect of fenofibrate and bezafibrate does not seem to be related to the hypolipidemic activity of the drugs. Fenofibrate 34-45 fibrinogen beta chain Homo sapiens 4-14 2731478-0 1989 [Effect of fenofibrate on fibrinogen concentration and blood viscosity. Fenofibrate 11-22 fibrinogen beta chain Homo sapiens 26-36 2731478-2 1989 The effect of fenofibrate (a clofibrate derivative) on fibrinogen concentration, blood viscosity and myocardial microcirculation was examined in 35 patients with coronary heart disease (n = 27) or hypertension (n = 8). Fenofibrate 14-25 fibrinogen beta chain Homo sapiens 55-65 31444987-7 2020 In men without macroprolactinaemia, fenofibrate decreased circulating levels of total and LDL cholesterol, triglycerides, uric acid, hsCRP and fibrinogen, and increased concentrations of HDL cholesterol, homocysteine and 25-hydroxyvitamin D, as well as improved insulin sensitivity. Fenofibrate 36-47 fibrinogen beta chain Homo sapiens 143-153 26031507-6 2015 Fenofibrate administered alone increased HDL cholesterol, reduced triglycerides, decreased insulin resistance, reduced circulating levels of uric acid, hsCRP, and fibrinogen, as well as increased plasma levels of homocysteine. Fenofibrate 0-11 fibrinogen beta chain Homo sapiens 163-173 26031507-7 2015 The strongest effect on testosterone, HOMA1-IR, uric acid, hsCRP, and fibrinogen was observed if fenofibrate was administered together with testosterone. Fenofibrate 97-108 fibrinogen beta chain Homo sapiens 70-80 23144467-6 2012 The effect of fenofibrate treatment on serum FGF21, but not RBP4, remained significant after adjusting for fenofibrate-induced changes in glycosylated hemoglobin, total cholesterol, triglycerides, apolipoprotein A-II, fibrinogen, plasma creatinine, and homocysteine (P = 0.002). Fenofibrate 14-25 fibrinogen beta chain Homo sapiens 218-228 23563040-3 2013 RESULTS: Twelve-week treatment with fenofibrate and metformin reduced plasma levels of fibrinogen and PAI-1 and tended to change the other hemostatic markers measured, as well as improved insulin sensitivity. Fenofibrate 36-47 fibrinogen beta chain Homo sapiens 87-97 21942979-3 2011 Fenofibrate also has nonlipid, pleiotropic effects (e.g. reducing levels of fibrinogen, C-reactive protein and various pro-inflammatory markers, and improving flow-mediated dilatation) that may contribute to its clinical efficacy, particularly in terms of improving microvascular outcomes. Fenofibrate 0-11 fibrinogen beta chain Homo sapiens 76-86 21675801-2 2011 Fenofibrate also has a number of nonlipid, pleiotropic effects (e.g. reducing levels of fibrinogen, C-reactive protein, and various pro-inflammatory markers, and improving flow-mediated dilatation) that may contribute to its clinical efficacy, particularly in terms of improving microvascular outcomes. Fenofibrate 0-11 fibrinogen beta chain Homo sapiens 88-98 24331137-4 2011 RESULTS: Fenofibrate significantly decreased systolic blood pressure, pulse wave velocity, serum insulin, insulin resistance (calculated from the homeostasis model assessment), total cholesterol, triglyceride, remnant-like particles cholesterol, uric acid, D-dimer, fibrinogen, serum amyloid A/low-density lipoprotein (LDL) and apoA1/LDL levels. Fenofibrate 9-20 fibrinogen beta chain Homo sapiens 266-276 15920062-6 2005 Fenofibrate significantly improved percent flow-mediated dilator response to hyperemia by 48 +/- 5% (P < 0.001) and lowered plasma levels of high-sensitivity C-reactive protein (hsCRP) relative to baseline measurements from 0.80 to 0.70 mg/l (P = 0.001) and fibrinogen levels by 16 +/- 3% (P < 0.001). Fenofibrate 0-11 fibrinogen beta chain Homo sapiens 261-271 19555253-7 2009 After 12 months, fibrinogen (Fg) decreased compared to baseline with fenofibrate + simvastatin. Fenofibrate 69-80 fibrinogen beta chain Homo sapiens 17-27 18650989-1 2007 OBJECTIVE: To find out whether the addition of fenofibrate to statin monotherapy produced any synergistic or additive beneficial effects in reducing risk factors, especially plasma fibrinogen, in patients with acute coronary syndrome (ACS) requiring percutaneous coronary interventions. Fenofibrate 47-58 fibrinogen beta chain Homo sapiens 181-191 18650989-9 2007 Statin monotherapy as well as its combination with fenofibrate produced a significant decrease in the fibrinogen levels. Fenofibrate 51-62 fibrinogen beta chain Homo sapiens 102-112 18650989-11 2007 Statins decreased plasma fibrinogen significantly, contrary to results from various reports, and the addition of fenofibrate further enhanced this reduction of the novel risk factor fibrinogen. Fenofibrate 113-124 fibrinogen beta chain Homo sapiens 182-192 17522372-5 2007 Micronized fenofibrate also significantly decreased fibrinogen (421 +/- 152 vs 344 +/- 81 mg/dl, p <0.001), hs-CRP (3.3 +/- 3.3 vs 2.1 +/- 1.8 mg/L, p <0.01), and ESR (19.1 +/- 24.8 vs 9.7 +/- 8.7 mm/hr, p <0.01), but did not change proinsulin levels. Fenofibrate 11-22 fibrinogen beta chain Homo sapiens 52-62 17522372-8 2007 In conclusion, after 12 wk, micronized fenofibrate therapy significantly decreased 3 inflammatory markers (hs-CRP, ESR, and fibrinogen) and improved the lipid profile by decreasing serum triglyceride, cholesterol, and non-HDL-cholesterol levels and increasing HDL-cholesterol; however, it did not change serum proinsulin level, a pancreatic stress marker. Fenofibrate 39-50 fibrinogen beta chain Homo sapiens 124-134 17209672-3 2007 Fenofibrate also has nonlipid (i.e. pleiotropic) effects (e.g. it reduces fibrinogen, C-reactive protein and uric acid levels and improves flow-mediated dilatation). Fenofibrate 0-11 fibrinogen beta chain Homo sapiens 74-84 19396049-3 2009 The aim was to determine the effect of fenofibrate treatment on Fb level, fibrinolysis, and platelet function in patients with MS with regard to smoking status and type 2 diabetes. Fenofibrate 39-50 fibrinogen beta chain Homo sapiens 64-66 19396049-7 2009 RESULTS: Fenofibrate treatment resulted in normalization of abnormal lipid profiles and a reduction in Fb level. Fenofibrate 9-20 fibrinogen beta chain Homo sapiens 103-105 19396049-11 2009 CONCLUSIONS: Fenofibrate partially corrected procoagulant state in patients with MS, which was manifested by a significant reduction in Fb level in all patients and inhibition of platelet function exclusively in nonsmokers. Fenofibrate 13-24 fibrinogen beta chain Homo sapiens 136-138 16875159-7 2006 The micronized fenofibrate caused a significant decrease in serum total cholesterol (by 15%), TG (by 38%), CRP (by 35%), fibrinogen (by 26%) and TBARS (by 33%) concentrations associated with a increase in CAT (by 35%), GSH-Px (by 63%), SOD (by 31%) activities. Fenofibrate 15-26 fibrinogen beta chain Homo sapiens 121-131 15877299-13 2005 There was no significant change in fibrinogen levels during the treatment of pravastatin and atorvastatin ( P > .05), but in fenofibrate group, fibrinogen levels were significantly decreased ( P < .05). Fenofibrate 128-139 fibrinogen beta chain Homo sapiens 147-157 16123850-6 2005 RESULTS: Fenofibrate decreased plasma fibrinogen level by 41% (from 3.9+/-0.9 mg/dl to 2.3+/-0.48 mg/dl, p<0.0001) and hs-CRP level by 71% (from 1.28 mg/dl to 0.36 mg/dl; p<0.0001). Fenofibrate 9-20 fibrinogen beta chain Homo sapiens 38-48 15877299-15 2005 Only fenofibrate has significant beneficial effects on the fibrinogen levels. Fenofibrate 5-16 fibrinogen beta chain Homo sapiens 59-69 15136070-5 2004 Fenofibrate reduced fibrinogen and plasminogen activator inhibitor type 1 antigen levels by 17 +/- 3 and 10 +/- 3%, respectively (P < 0.001 and P = 0.014, respectively). Fenofibrate 0-11 fibrinogen beta chain Homo sapiens 20-30 14764586-7 2004 A similar global effect of fenofibrate on acute phase protein expression is observed in hyperlipidemic patients chronically treated with fenofibrate, which displayed decreased plasma concentrations of the positive APR proteins fibrinogen, C-reactive protein, serum amyloid A, plasminogen, and alpha2-macroglobulin and increased plasma concentrations of the negative APR albumin, underlining the clinical significance of our findings. Fenofibrate 27-38 fibrinogen beta chain Homo sapiens 227-237 14764586-7 2004 A similar global effect of fenofibrate on acute phase protein expression is observed in hyperlipidemic patients chronically treated with fenofibrate, which displayed decreased plasma concentrations of the positive APR proteins fibrinogen, C-reactive protein, serum amyloid A, plasminogen, and alpha2-macroglobulin and increased plasma concentrations of the negative APR albumin, underlining the clinical significance of our findings. Fenofibrate 137-148 fibrinogen beta chain Homo sapiens 227-237